|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: IP6K2 |
Gene summary for IP6K2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | IP6K2 | Gene ID | 51447 |
| Gene name | inositol hexakisphosphate kinase 2 | |
| Gene Alias | IHPK2 | |
| Cytomap | 3p21.31 | |
| Gene Type | protein-coding | GO ID | GO:0001558 | UniProtAcc | B2RCP4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51447 | IP6K2 | HTA11_1938_2000001011 | Human | Colorectum | AD | 4.76e-03 | 4.88e-01 | -0.0811 |
| 51447 | IP6K2 | HTA11_347_2000001011 | Human | Colorectum | AD | 4.01e-14 | 6.46e-01 | -0.1954 |
| 51447 | IP6K2 | HTA11_696_2000001011 | Human | Colorectum | AD | 9.63e-03 | 4.07e-01 | -0.1464 |
| 51447 | IP6K2 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 5.09e-06 | 5.46e-01 | 0.294 |
| 51447 | IP6K2 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 1.15e-03 | 5.42e-01 | 0.281 |
| 51447 | IP6K2 | A002-C-010 | Human | Colorectum | FAP | 3.11e-02 | -1.35e-01 | 0.242 |
| 51447 | IP6K2 | A015-C-203 | Human | Colorectum | FAP | 5.06e-24 | -7.95e-02 | -0.1294 |
| 51447 | IP6K2 | A015-C-204 | Human | Colorectum | FAP | 1.53e-03 | -4.43e-02 | -0.0228 |
| 51447 | IP6K2 | A002-C-201 | Human | Colorectum | FAP | 4.32e-09 | -5.00e-02 | 0.0324 |
| 51447 | IP6K2 | A002-C-203 | Human | Colorectum | FAP | 8.36e-05 | -1.14e-01 | 0.2786 |
| 51447 | IP6K2 | A001-C-119 | Human | Colorectum | FAP | 3.33e-02 | -1.91e-01 | -0.1557 |
| 51447 | IP6K2 | A001-C-108 | Human | Colorectum | FAP | 4.10e-16 | -1.82e-01 | -0.0272 |
| 51447 | IP6K2 | A002-C-205 | Human | Colorectum | FAP | 3.00e-17 | -2.62e-01 | -0.1236 |
| 51447 | IP6K2 | A001-C-104 | Human | Colorectum | FAP | 2.06e-04 | -1.07e-01 | 0.0184 |
| 51447 | IP6K2 | A015-C-006 | Human | Colorectum | FAP | 8.01e-13 | -1.88e-01 | -0.0994 |
| 51447 | IP6K2 | A015-C-106 | Human | Colorectum | FAP | 6.26e-13 | -1.10e-01 | -0.0511 |
| 51447 | IP6K2 | A002-C-114 | Human | Colorectum | FAP | 1.71e-13 | -2.26e-01 | -0.1561 |
| 51447 | IP6K2 | A015-C-104 | Human | Colorectum | FAP | 5.28e-27 | -1.49e-01 | -0.1899 |
| 51447 | IP6K2 | A001-C-014 | Human | Colorectum | FAP | 1.77e-15 | -1.89e-01 | 0.0135 |
| 51447 | IP6K2 | A002-C-016 | Human | Colorectum | FAP | 1.08e-19 | -2.58e-01 | 0.0521 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00066505 | Esophagus | ESCC | glycerophospholipid metabolic process | 174/8552 | 306/18723 | 4.92e-05 | 3.85e-04 | 174 |
| GO:00464864 | Esophagus | ESCC | glycerolipid metabolic process | 211/8552 | 392/18723 | 6.51e-04 | 3.46e-03 | 211 |
| GO:00303085 | Esophagus | ESCC | negative regulation of cell growth | 108/8552 | 188/18723 | 7.46e-04 | 3.87e-03 | 108 |
| GO:00461653 | Esophagus | ESCC | alcohol biosynthetic process | 83/8552 | 140/18723 | 8.04e-04 | 4.16e-03 | 83 |
| GO:19016174 | Esophagus | ESCC | organic hydroxy compound biosynthetic process | 128/8552 | 237/18723 | 5.86e-03 | 2.16e-02 | 128 |
| GO:00066611 | Esophagus | ESCC | phosphatidylinositol biosynthetic process | 73/8552 | 131/18723 | 1.31e-02 | 4.28e-02 | 73 |
| GO:000606612 | Liver | Cirrhotic | alcohol metabolic process | 141/4634 | 353/18723 | 1.57e-10 | 8.03e-09 | 141 |
| GO:001604911 | Liver | Cirrhotic | cell growth | 160/4634 | 482/18723 | 1.50e-05 | 2.07e-04 | 160 |
| GO:0046165 | Liver | Cirrhotic | alcohol biosynthetic process | 55/4634 | 140/18723 | 9.74e-05 | 1.03e-03 | 55 |
| GO:000155811 | Liver | Cirrhotic | regulation of cell growth | 132/4634 | 414/18723 | 5.53e-04 | 4.36e-03 | 132 |
| GO:19016171 | Liver | Cirrhotic | organic hydroxy compound biosynthetic process | 81/4634 | 237/18723 | 6.73e-04 | 5.06e-03 | 81 |
| GO:000606621 | Liver | HCC | alcohol metabolic process | 208/7958 | 353/18723 | 2.80e-10 | 9.50e-09 | 208 |
| GO:001604921 | Liver | HCC | cell growth | 269/7958 | 482/18723 | 1.84e-09 | 5.35e-08 | 269 |
| GO:00086542 | Liver | HCC | phospholipid biosynthetic process | 150/7958 | 253/18723 | 4.77e-08 | 1.03e-06 | 150 |
| GO:00066444 | Liver | HCC | phospholipid metabolic process | 214/7958 | 383/18723 | 7.25e-08 | 1.48e-06 | 214 |
| GO:000155821 | Liver | HCC | regulation of cell growth | 228/7958 | 414/18723 | 1.34e-07 | 2.55e-06 | 228 |
| GO:004648611 | Liver | HCC | glycerolipid metabolic process | 215/7958 | 392/18723 | 4.54e-07 | 7.49e-06 | 215 |
| GO:004501711 | Liver | HCC | glycerolipid biosynthetic process | 143/7958 | 252/18723 | 3.27e-06 | 4.31e-05 | 143 |
| GO:00066504 | Liver | HCC | glycerophospholipid metabolic process | 168/7958 | 306/18723 | 7.27e-06 | 8.62e-05 | 168 |
| GO:004647411 | Liver | HCC | glycerophospholipid biosynthetic process | 121/7958 | 211/18723 | 9.12e-06 | 1.06e-04 | 121 |
| Page: 1 2 3 4 5 6 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa04070 | Colorectum | CRC | Phosphatidylinositol signaling system | 25/1091 | 97/8465 | 4.27e-04 | 4.60e-03 | 3.12e-03 | 25 |
| hsa040701 | Colorectum | CRC | Phosphatidylinositol signaling system | 25/1091 | 97/8465 | 4.27e-04 | 4.60e-03 | 3.12e-03 | 25 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| IP6K2 | SNV | Missense_Mutation | c.634C>A | p.Arg212Ser | p.R212S | Q9UHH9 | protein_coding | tolerated(0.14) | benign(0.283) | TCGA-A8-A09C-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| IP6K2 | insertion | In_Frame_Ins | novel | c.824_825insTTT | p.Tyr275_His276insPhe | p.Y275_H276insF | Q9UHH9 | protein_coding | TCGA-A8-A07Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unspecific | Exemestane | SD | ||
| IP6K2 | insertion | Frame_Shift_Ins | novel | c.823_824insCTTTATTTATTTTAACTATTTCTTCAACATTCCAC | p.Tyr275SerfsTer49 | p.Y275Sfs*49 | Q9UHH9 | protein_coding | TCGA-A8-A07Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unspecific | Exemestane | SD | ||
| IP6K2 | insertion | Nonsense_Mutation | novel | c.635_636insAGGAATCAGCTGATGAGTCTGCT | p.Tyr213GlyfsTer4 | p.Y213Gfs*4 | Q9UHH9 | protein_coding | TCGA-A8-A09C-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| IP6K2 | insertion | In_Frame_Ins | novel | c.50_51insGGGGGAAGACTTTGGGAGGATTTTACCCAGAATACTTGC | p.Val17_Leu18insGlyGluAspPheGlyArgIleLeuProArgIleLeuAla | p.V17_L18insGEDFGRILPRILA | Q9UHH9 | protein_coding | TCGA-AN-A0FN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| IP6K2 | insertion | Frame_Shift_Ins | novel | c.92_93insG | p.Cys31TrpfsTer7 | p.C31Wfs*7 | Q9UHH9 | protein_coding | TCGA-B6-A0RH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | ||
| IP6K2 | deletion | Frame_Shift_Del | novel | c.354delN | p.Lys118AsnfsTer5 | p.K118Nfs*5 | Q9UHH9 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| IP6K2 | SNV | Missense_Mutation | c.1006G>A | p.Asp336Asn | p.D336N | Q9UHH9 | protein_coding | deleterious(0.02) | probably_damaging(0.995) | TCGA-EA-A1QS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| IP6K2 | SNV | Missense_Mutation | novel | c.703G>A | p.Glu235Lys | p.E235K | Q9UHH9 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-EK-A2RM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| IP6K2 | SNV | Missense_Mutation | novel | c.177N>A | p.Met59Ile | p.M59I | Q9UHH9 | protein_coding | tolerated(0.06) | benign(0) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |